- |||||||||| 23ME-00610 / 23andMe
Trial completion date, Trial primary completion date, Tumor mutational burden: 23ME-00610-CLIN-001: A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies (clinicaltrials.gov) - May 22, 2024 P1/2, N=141, Active, not recruiting, Based on PK/PD, safety, and preliminary anti-tumor activity, 1400 mg Q3W was selected as the dose for further study. Trial completion date: Jun 2024 --> Mar 2025 | Trial primary completion date: Jun 2024 --> Mar 2025
- |||||||||| 23ME-00610 / 23andMe
New insights into targeting the CD200R1 pathway in T and NK cells using 23ME-00610 as a single agent or in combination (Section 38) - Mar 5, 2024 - Abstract #AACR2024AACR_3752; P1/2 Taken together, these data demonstrate that 23ME-00610 can enhance both NK and T cell antitumor effector functions, and 23ME-00610 could synergize with anti-PD-1 to further increase the activity of T cells against cancer cells. The results of this study provide evidence that 23ME-00610 could expand IO treatment options for patients with advanced solid malignancies as a single agent or in combination with other anti-tumor therapeutics.
|